Revumenib (Synonyms: SNDX-5613)

Name: Revumenib
Brand: MedChemExpress
SKU: HY-136175
Rating: 5.0 (15 reviews)

Cat. No.: HY-136175 Pureza: 99.99%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 2169919-21-3

Tamaño	Stock	Cantidad

Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	Obtener un presupuesto
500 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 15 publication(s) in Google Scholar

Other Forms of Revumenib:

cis-Revumenib In-stock

15 Publications Citing Use of MCE Revumenib

Cell Proliferation/Viability Assay

RT-PCR

2D/3D Cell Culture and Differentiation

In Vivo Efficacy Study

: Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]; Primary tumors from 5 individual patients (Pt1-5) harboring a UBTF-TD alteration treated with menin inhibitor SNDX-5613 (2.5-2500 nM; 4-14 d) in vitro. Primary sample from a single patient with a RUNX1::RUNX1T1 alteration was used as a control.

: Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]; MEIS1 mRNA steady-state levels in patient cells treated with SNDX-5613 (2.5-2500 nM).

: Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]; CFU capacity of UBTF-TD leukemias after exposure to SNDX-5613. Cells from Pt4 and Pt5 were treated with SNDX-5613 (250 nM; 12 d) and then plated in methylcellulose.

: Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]; Kaplan-Meier curves of UBTF-TD PDX model treated with vehicle or SNDX-5613 ( 75 mg/kg; p.o. twice daily (5 days on, 2 days off) for 5 weeks).

: Revumenib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]; Relative viability of MOLM-13 cells measured after 6 days treatment of DMSO or M WM-1119, and increasing concentrations of indicated chemicals (SNDX-5613).

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

IC₅₀ & Target

Menin-MLL^[1]

In Vivo

Revumenib shows in vivo plasma IC₅₀ of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

Peso molecular

630.82

Fòrmula

C₃₂H₄₇FN₆O₄S

No. CAS

2169919-21-3

Appearance

Solid

Color

White to off-white

SMILES

O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvente y solubilidad

In Vitro:

DMSO : ≥ 25 mg/mL (39.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5852 mL	7.9262 mL	15.8524 mL
5 mM	0.3170 mL	1.5852 mL	3.1705 mL
10 mM	0.1585 mL	0.7926 mL	1.5852 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
Protocol 6

Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.5 mg/mL (0.79 mM); Clear solution

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 20 mg/mL (31.70 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.99%

Select Batch:

Ficha de datos (275 KB) SDS (394 KB)

COA (252 KB) HNMR (320 KB) RP-HPLC (254 KB) MS (68 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.5852 mL	7.9262 mL	15.8524 mL	39.6310 mL
	5 mM	0.3170 mL	1.5852 mL	3.1705 mL	7.9262 mL
	10 mM	0.1585 mL	0.7926 mL	1.5852 mL	3.9631 mL
	15 mM	0.1057 mL	0.5284 mL	1.0568 mL	2.6421 mL
	20 mM	0.0793 mL	0.3963 mL	0.7926 mL	1.9815 mL
	25 mM	0.0634 mL	0.3170 mL	0.6341 mL	1.5852 mL
	30 mM	0.0528 mL	0.2642 mL	0.5284 mL	1.3210 mL

Revumenib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Revumenib2169919-21-3SNDX-5613SNDX5613SNDX 5613Epigenetic Reader DomainMeninMLLLeukemiaacutelymphoblasticALLmyeloidAMLInhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Revumenib (Synonyms: SNDX-5613)

Revisión del cliente

Other Forms of Revumenib:

Revumenib Related Antibodies

15 Publications Citing Use of MCE Revumenib

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Revumenib Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report